Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, multicenter, phase II trial to investigate the efficacy and safety of sintilimab (anti-PD-1 antibody) in combination with anlotinib plus metronomic chemotherapy as a potential novel therapeutic strategy in advanced triple negative breast cancer

Next Previous
Search
Trial Profile

A single-arm, multicenter, phase II trial to investigate the efficacy and safety of sintilimab (anti-PD-1 antibody) in combination with anlotinib plus metronomic chemotherapy as a potential novel therapeutic strategy in advanced triple negative breast cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Catequentinib (Primary) ; Sintilimab (Primary) ; Vinorelbine (Primary)
  • Indications Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms SPACE

    • Most Recent Events

    • 29 Aug 2024 According to an Innovent Biologics media release, data from this trial will be presented at the European Society of Medical Oncology (ESMO) from Sept 13-17, 2024, in Barcelona, Spain.
    • 24 Oct 2023 Preliminary Results (As of April 2023, n=38) assessing Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer presented at the 48th European Society for Medical Oncology Congress
    • 08 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top